Sesen Launches with a Singular Mission: Advancing Life Sciences Globally Through Specialized Language Solutions
BOSTON--(BUSINESS WIRE)--Today marks the official launch of Sesen, a next-generation language services company purpose-built to meet the complex demands of the life sciences industry. Specializing exclusively in translation, localization, and AI-enhanced linguistic solutions for pharmaceutical, biotechnology, medical device, CRO, and regulatory organizations, Sesen combines industry expertise with cutting-edge technology to deliver fast, accurate, and fully compliant multilingual communications across 150+ languages.
Built by industry veterans, Sesen is redefining how life sciences companies manage language workflows, from clinical trial documentation and regulatory labeling to patient communications and digital health platforms. At the core of its offering is SesenGPT, a proprietary AI engine trained on life sciences terminology and optimized for medical and regulatory content.
Key Capabilities Include:
Regulatory-compliant translations aligned with EMA, FDA, and PMDA guidelines
ISO 17100, ISO 9001:2015, and ISO 13485:2016 certified quality management
AI-enabled hybrid workflows for clinical trial translations, pharmacovigilance, and labeling
Native linguists and MD/PhD medical reviewers for domain-specific accuracy
Scalable language solutions integrated with sponsor CMS and eTMF systems
'Life sciences innovation is increasingly global, but language remains a critical barrier,' said Dr. Vladimir Misik, VP of Global Clinical Trial Strategy. 'We launched Sesen to solve this challenge with unmatched specialization, seamless technology integration, and the linguistic precision this industry demands.'
Diego Di Leva, Sesen's VP of Global Operations, and a certified ISO 9001 and ISO 13485 auditor, added:
"At Sesen, language quality is not an afterthought, it's built into the DNA of every project. Our quality assurance framework is grounded in international standards and supported by linguists with deep domain expertise, ensuring every deliverable meets the highest regulatory and scientific expectations."
With a growing network of linguists, in-country reviewers, and regulatory consultants, Sesen supports top pharmaceutical and biotechnology companies with on-time, compliant delivery of multilingual assets for product launches, clinical trials, and regulatory submissions.
About Sesen
Sesen is a specialized language solutions provider exclusively serving the life sciences industry. Focused on clinical, regulatory, and commercial translation, Sesen supports pharmaceutical, biotech, medical device, and CRO clients in 150+ languages. The company combines native linguists, medical professionals, and ISO-certified workflows with proprietary AI technology to deliver faster, more accurate, and compliant content. From clinical trial support to product localization, Sesen enables life sciences organizations to operate with linguistic confidence and regulatory precision. www.sesen.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will host a webcast and conference call on June 30, 2025, at 8:30 a.m. ET to discuss AUR200 Phase 1 study results. The link to the webcast is available here. To join the conference call, please dial 877-407-9170/+1 201-493-6756. Click here for participant International Toll-Free access numbers. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.
Business Wire
2 days ago
- Business Wire
Rocket Lab Completes Record Launch Turnaround From Launch Complex 1, Successfully Deploys 68 th Electron Mission
MAHIA, New Zealand--(BUSINESS WIRE)--Rocket Lab Corporation (Nasdaq: RKLB) ('Rocket Lab' or 'the Company'), a global leader in launch services and space systems, today successfully launched its 68th Electron rocket to deploy a single satellite to space for a confidential commercial customer. The mission was the second of two launches from the same launch site in less than 48 hours, a new launch record for the Company as it continues to deliver dedicated, repeatable and reliable access to space for satellite operators. The 'Symphony In The Stars' mission lifted-off from Rocket Lab Launch Complex 1 in Mahia, New Zealand on June 28 th (7:08 p.m./07:08 UTC) to deploy a single spacecraft to a 650km circular Earth orbit. The mission was the first of two dedicated launches for the new customer on Electron booked less than four months ago, with a second mission scheduled before the end of 2025. Rocket Lab has now completed four launches in June for commercial satellite constellation operators, underscoring Electron's consistent performance and rapid deployment capabilities as the world's leading small launcher: the 'Full Stream Ahead' mission on June 3 rd; 'The Mountain God Guards' mission on June 11 th; 'Get The Hawk Outta Here' launched on June 26 th UTC, and today's 'Symphony In The Stars' mission. Rocket Lab Founder and CEO, Sir Peter Beck, says: 'Electron has demonstrated once again that it is the gold standard for responsive and reliable space access for small satellites. The future of space is built on proven performance, and Electron continues to deliver against a stacked launch manifest this year. Congratulations to the team on achieving its fastest launch turnaround yet between two missions from Launch Complex 1. This launch was also a quick-turn mission to meet our customer's mission requirements, and we're looking forward to doing it again later this year.' 'Symphony In The Stars' was Rocket Lab's tenth Electron mission of 2025 and its 68th launch overall. With 100% mission success so far this year, Electron continues to deliver reliable deployment amid an increasing launch cadence and rapid contract-to-launch timelines. Launch images: About Rocket Lab Founded in 2006, Rocket Lab is an end-to-end space company with an established track record of mission success. We deliver reliable launch services, satellite manufacture, spacecraft components, and on-orbit management solutions that make it faster, easier, and more affordable to access space. Headquartered in Long Beach, California, Rocket Lab designs and manufactures the Electron small orbital launch vehicle, a family of spacecraft platforms, and the Company is developing the large Neutron launch vehicle for constellation deployment. Since its first orbital launch in January 2018, Rocket Lab's Electron launch vehicle has become the second most frequently launched U.S. rocket annually and has delivered over 200 satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. Rocket Lab's spacecraft platforms have been selected to support NASA missions to the Moon and Mars, as well as the first private commercial mission to Venus. Rocket Lab has three launch pads at two launch sites, including two launch pads at a private orbital launch site located in New Zealand and a third launch pad in Virginia. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward looking statements contained in Section 27A of the Securities Act of 1933, as amended (the 'Securities Act') and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'). All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our launch and space systems operations, launch schedule and window, safe and repeatable access to space, Neutron development, operational expansion and business strategy are forward-looking statements. The words 'believe,' 'may,' 'will,' 'estimate,' 'potential,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'strategy,' 'future,' 'could,' 'would,' 'project,' 'plan,' 'target,' and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to the factors, risks and uncertainties included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission (the 'SEC'), accessible on the SEC's website at and the Investor Relations section of our website at which could cause our actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
Yahoo
2 days ago
- Yahoo
TD Cowen Starts Coverage Soleno Therapeutics (SLNO) Stock, Gives Buy
Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the 10 Unstoppable Stocks to Buy According to Hedge Funds. On June 23, TD Cowen analyst Tyler Van Buren began coverage of the company's stock with a 'Buy' rating and a price objective of $110, as reported by The Fly. The firm highlighted VYKAT XR as the first-approved treatment for hyperphagia in Prader-Willi syndrome (PWS). As per the firm, the drug bucked the trend of clinical shortcomings in PWS by securing the regulatory approval. A clinical-stage biopharmaceutical company's boardroom, emphasizing the importance of decision-making for the lead candidate development of a once-daily oral tablet. The firm demonstrated confidence in Soleno Therapeutics, Inc. (NASDAQ:SLNO)'s management team, mentioning that they seem to be prepared to execute a strong launch with a high price tag and sizable population to itself. The analysis exhibits that the company has positioned itself for commercial success. The firm remains optimistic and believes that the PWS community's urgency is expected to drive significant uptake of VYKAT XR, reflecting robust demand potential among patients and caregivers. Soleno Therapeutics, Inc. (NASDAQ:SLNO) also announced that its Marketing Authorization Application (MAA) seeking regulatory approval of Diazoxide Choline Prolonged-Release Tablets for the treatment of adults and children aged 4 years and older with PWS, who possess hyperphagia, had been validated by the EMA (European Medicines Agency). TimesSquare Capital Management, an equity investment management company, released its Q1 2025 investor letter. Here is what the fund said: 'Our preferences among Health Care stocks are those companies providing novel therapies for unmet needs that deserve premium pricing, or specialized service providers. Soleno Therapeutics, Inc. (NASDAQ:SLNO) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for rare diseases. The FDA granted approval of Vyvkat for treating Prader Willi syndrome, a rare genetic disorder that causes life-threatening obesity in children. That development served to boost the stock price by 60% and we decided to book some of the profits by cutting back on the investment.' While we acknowledge the potential of SLNO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SLNO and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
